Donepezil Hydrochloride Torrent Pharma (Uk) (Donepezil Hydrochloride)

Donepezil Hydrochloride Torrent Pharma is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease.

• Improves cognitive function such as memory and attention in patients with Alzheimer’s disease.
• May support activities of daily living by modestly enhancing functional abilities.
• Used as part of a comprehensive care plan that includes non‑pharmacologic interventions.
• Prescribed when a clinician determines that cholinergic deficiency contributes to the patient’s cognitive decline.
• May be considered for patients who have not responded adequately to other cholinesterase inhibitors.
• Can be continued as long as clinical benefit outweighs tolerability concerns, with periodic reassessment by the treating physician.

The safety profile of Donepezil Hydrochloride includes both common, generally mild reactions and less frequent serious adverse events.

Common

• Nausea, vomiting, or abdominal discomfort, which are usually transient and may improve with food.
• Diarrhea, loose stools, or constipation, often mild and manageable with dietary adjustments.
• Insomnia, vivid dreams, or fatigue, which can affect sleep quality.

Serious

• Bradycardia, sinus node dysfunction, or atrioventricular block, potentially requiring cardiac monitoring.
• Gastrointestinal ulceration or bleeding, especially in patients with a history of peptic ulcer disease.
• Seizures or severe muscle weakness, which are rare but warrant immediate medical attention.
• Hepatotoxicity or abnormal liver function tests, monitored through periodic laboratory assessment.
• Severe allergic reactions such as rash, angioedema, or anaphylaxis, requiring prompt discontinuation.

When prescribing Donepezil Hydrochloride, clinicians consider several precautionary factors to ensure safe use.

• Assess cardiac history, especially bradyarrhythmias, before initiating therapy.
• Review concomitant medications that may lower heart rate or interact with cholinesterase inhibitors.
• Evaluate gastrointestinal risk, including history of ulcers or bleeding disorders.
• Monitor liver function periodically, as hepatic impairment can affect drug metabolism.
• Use caution in patients with asthma or chronic obstructive pulmonary disease due to possible bronchospasm.
• Adjust dose or avoid use in severe renal impairment, as excretion may be reduced.

Donepezil Hydrochloride may interact with other medicines, influencing its efficacy or safety.

Avoid

• Concurrent use with other cholinesterase inhibitors (e.g., rivastigmine, galantamine) due to additive cholinergic effects.
• Combination with strong anticholinergic agents (e.g., diphenhydramine, atropine) which may counteract therapeutic action.
• Co‑administration with drugs that significantly prolong the QT interval, increasing cardiac risk.

Use with caution

• Beta‑blockers or calcium‑channel blockers, which can exacerbate bradycardia.
• NSAIDs or anticoagulants, raising the risk of gastrointestinal bleeding.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) that may increase donepezil plasma concentrations.
• Anticonvulsants such as carbamazepine, which could reduce donepezil levels via enzyme induction.
• Herbal supplements like ginkgo biloba, which could have additive cholinergic activity.